-
Agreement with Biogen to buyout Biogen’s (50% -1 share) stake in Samsung Bioepis Joint Venture for up to USDÂ $2.3 billion
-
Transaction projected to be accretive to earnings in 2022 and thereafter, fully capitalizing on the high growth potential of Samsung Bioepis
-
Expected to accelerate growth in biosimilars and novel therapeutics R&D
-
Purchase to be funded through a portion of KRW 3 trillion paid-in capital increase, focused on investment in Samsung Biologics’ future growth
Samsung Biologics announced that it has reached an agreement with Biogen for the buyout of Biogen’s stake in the Samsung Bioepis joint venture for USDÂ $2.3 billion. The transaction is expected to boost earnings growth of Samsung Biologics on a consolidated basis, fully capitalizing on Samsung Bioepis’ growth outlook.
The Board of Directors of Samsung Biologics has approved the transaction, in which payment for the shares will be made in installments over the next two years, and full ownership will take effect at the time the first payment of USD $1.0 billion is made. The Board has also agreed to raise capital of KRW 3 trillion (approximately USD $2.5 billion) by issuing new shares, the proceeds of which will be used to fund the company’s strategic growth plans, including the purchase of the Samsung Bioepis shares.
Biogen initially invested in a 15% stake in Samsung Bioepis when it was established as a joint venture in 2012. Under the terms of the original agreement, Biogen had the right to purchase up to 50% less one share of Samsung Bioepis, which it exercised in June 2018.
Top iTechnology Networking News: Portnox Closes $22 Million Series A to Make Cloud-Native Network & Endpoint Security a Reality
The deal will further deliver Samsung Bioepis’ sales growth and operating margin improvements with streamlined operational efficiencies, budget surplus, and cash flow generation. Samsung Bioepis has successfully launched five biosimilars globally, three in autoimmune and two in oncology. Additionally, one product is about to be released in the market, and four biosimilars are in Phase 3 clinical trials. The full buyout of Biogen’s stake is expected to accelerate Samsung Bioepis’ biosimilar development capabilities and future performance in novel drug development, with improved autonomy and agility in business operations.
Meanwhile, Samsung’s Biologics will continue to deliver quality-driven biomanufacturing services, with existing firewalls between Samsung’s Bioepis, and expand its biopharmaceutical business in its three core drivers: continued capacity enhancement, establishment of growth opportunities in new business areas, such as mRNA and cell and gene therapies, and global expansion.
Samsung’s Biologics is currently building Plant 4, which will break its own record of holding the world’s largest biomanufacturing capacity, and will begin construction this year of a new facility, Plant 5, which will offer multi-modal product services. In addition, the company is in the process of securing additional land of 350,000m2 for Bio Campus II, which will be 30% larger than the size of the current site.
Through these milestones, Samsung’s Biologics continues to deliver on its commitment to its clients and shareholders as a top-tier biopharmaceutical company, while advancing the industry with unparalleled innovation, quality, and client satisfaction.
Top iTechnology Cloud News: Ingram Micro Strengthens Its Cloud Platform With Acquisition of Keenondots
[To share your insights with us, please write to sghosh@martechseries.com]
